APOE and COVID-19: Nevertheless, our study supports the notion that APOE4 associates with disease severity, as documented by the increased inflammation in COVID-19 patients with APOE ε4 genotype, and weaker ability of APOE4 in inhibiting cellular entry of SARS-CoV-2, when compared to the ε3 carriers and APOE3, respectively.